BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/15/2020 12:32:18 PM | Browse: 1405 | Download: 3004
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 51979
Country South Korea
ISSN 1948-5204 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Retrospective Cohort Study
Article Title FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
Manuscript Source Unsolicited Manuscript
All Author List In Rae Cho, Huapyong Kang, Jung Hyun Jo, Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song, Chansik An, Mi-Suk Park and Seungmin Bang
ORCID
Author(s) ORCID Number
In Rae Cho http://orcid.org/0000-0001-9874-5526
Huapyong Kang http://orcid.org/0000-0003-1790-0809
Jung Hyun Jo http://orcid.org/0000-0002-2641-8873
Hee Seung Lee http://orcid.org/0000-0002-2825-3160
Moon Jae Chung http://orcid.org/0000-0002-5920-8549
Jeong Youp Park http://orcid.org/0000-0003-0110-8606
Seung Woo Park http://orcid.org/0000-0001-8230-964X
Si Young Song http://orcid.org/0000-0002-1417-4314
Chansik An http://orcid.org/0000-0002-0484-6658
Mi-Suk Park http://orcid.org/0000-0001-5817-2444
Seungmin Bang http://orcid.org/0000-0001-5209-8351
Funding Agency and Grant Number
Corresponding Author Seungmin Bang, MD, PhD, Professor, Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Select, South Korea. bang7028@yuhs.ac
Key Words Pancreatic cancer; Chemotherapy; FOLFIRINOX; Gemcitabine; Nab-paclitaxel; Survival
Core Tip Both FOLFIRINOX and gemcitabine plus nab-paclitaxel combination therapy are widely used as a treatment of choice in patients with metastatic pancreatic cancer. However, the treatment choice and sequence are not firmly established. In addition, researches on Asian populations in this regard are scarce. In the present study, we compared the treatment efficacy, safety, and economic aspects of FOLFIRINOX and gemcitabine plus nab-paclitaxel combination therapy. We believe that this study can help physicians and patients to select appropriate regimens while avoiding and preventing unnecessary complications.
Publish Date 2020-02-15 12:32
Citation Cho IR, Kang H, Jo JH, Lee HS, Chung MJ, Park JY, Park SW, Song SY, An C, Park MS, Bang S. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. World J Gastrointest Oncol 2020; 12(2): 182-194
URL https://www.wjgnet.com/1948-5204/full/v12/i2/182.htm
DOI https://dx.doi.org/10.4251/wjgo.v12.i2.182
Full Article (PDF) WJGO-12-182.pdf
Full Article (Word) WJGO-12-182.docx